Astrazeneca Plc (NYSE:AZN) Receives $205.33 Average Price Target from Brokerages

Astrazeneca Plc (NYSE:AZN) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and twelve have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $205.3333.

AZN has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “buy (b)” rating on shares of Astrazeneca in a report on Monday, June 8th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Finally, Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st.

Institutional Investors Weigh In On Astrazeneca

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AZN. Mascoma Wealth Management LLC bought a new position in Astrazeneca in the 1st quarter worth $26,000. MV Capital Management Inc. bought a new position in Astrazeneca in the 4th quarter worth $26,000. Reflection Asset Management bought a new position in Astrazeneca in the 4th quarter worth $31,000. Resources Management Corp CT ADV bought a new position in Astrazeneca in the 1st quarter worth $35,000. Finally, Raleigh Capital Management Inc. bought a new position in Astrazeneca in the 1st quarter worth $38,000. 20.35% of the stock is currently owned by institutional investors.

Astrazeneca Price Performance

Shares of Astrazeneca stock opened at $177.36 on Tuesday. Astrazeneca has a 52-week low of $137.23 and a 52-week high of $212.71. The stock has a market capitalization of $275.07 billion, a price-to-earnings ratio of 26.63, a price-to-earnings-growth ratio of 1.55 and a beta of 0.25. The company has a fifty day moving average of $188.74 and a 200-day moving average of $186.10. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Equities research analysts expect that Astrazeneca will post 9.39 EPS for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.